Syncope in congestive heart failure

Cardiology Journal

Volumn 15, Issue 4, 2008, Pages 303-312

  Gopinathannair, Rakesh ^a   Mazur, Alexander ^a   Olshansky, Brian ^a  

^a UNIVERSITY OF IOWA HOSPITALS AND CLINICS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARDIOMYOPATHY; CONGESTIVE HEART FAILURE; DEFIBRILLATOR; ELECTROCARDIOGRAPHY MONITORING; HEART DISEASE; HEART ELECTROPHYSIOLOGY; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FAILURE; HEART VENTRICLE TACHYCARDIA; HIGH RISK PATIENT; HUMAN; MORTALITY; PATHOGENESIS; PHYSICAL EXAMINATION; PROGNOSIS; REVIEW; SYNCOPE; T WAVE; AGED; ELECTROCARDIOGRAPHY; FEMALE; HEART FAILURE; HOSPITALIZATION; MALE; METHODOLOGY; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; SURVIVAL RATE; TREATMENT OUTCOME;

AMIODARONE;

AGED; AGED, 80 AND OVER; AMIODARONE; COMBINED MODALITY THERAPY; DEFIBRILLATORS, IMPLANTABLE; ELECTROCARDIOGRAPHY; ELECTROCARDIOGRAPHY, AMBULATORY; FEMALE; HEART FAILURE; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; SURVIVAL RATE; SYNCOPE; TREATMENT OUTCOME;

EID: 55249096275     PISSN: 18975593     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (44)

1. Kapoor WN. Workup and management of patients with syncope. Med Clin North Am, 1995; 79: 1153-1170.
2. Soteriades ES, Evans JC, Larson MG et al. Incidence and prognosis of syncope. N Engl J Med, 2002; 347: 878-885.
3. Kapoor WN, Hanusa BH. Is syncope a risk factor for poor outcomes? Comparison of patients with and without syncope. Am J Med, 1996; 100: 646-655.
4. Martin TP, Hanusa BH, Kapoor WN. Risk stratification of patients with syncope. Ann Emerg Med 1997; 29: 459-466.
5. Olshansky B, Hahn EA, Hartz VL, Prater SP, Mason JW. Clinical significance of syncope in the electrophysiologic study versus electrocardiographic monitoring (ESVEM) trial. the ESVEM investigators. Am Heart J, 1999; 137: 878-886.
6. Grimm W, Hoffmann JJ, Muller HH, Maisch B. Implantable defibrillator event rates in patients with idiopathic dilated cardiomyopathy, nonsustained ventricular tachycardia on holter and a left ventricular ejection fraction below 30%. J Am Coll Cardiol, 2002; 39: 780-787.
7. Turrini P, Corrado D, Basso C, Nava A, Thiene G. Noninvasive risk stratification in arrhythmogenic right ventricular cardiomyopathy. Ann Electrocardiol, 2003; 8: 161-169.
8. Brugada R, Hong K, Cordeiro JM, Dumaine R. Short QT syndrome. CMAJ, 2005; 173: 1349-1354.
9. Vohra J. The long QT syndrome. Heart Lung Circ, 2007; 16 (Suppl. 3): S5-S12.
10. Antzelevitch C. Brugada syndrome, Pacing Clin Electrophysiol, 2006; 29: 1130-1159.
11. Behr ER, Elliott P, McKenna WJ. Role of invasive EP testing in the evaluation and management of hypertrophic cardiomyopathy. Card Electrophysiol Rev, 2002; 6: 482-486.
12. Middlekauff HR, Stevenson WG, Stevenson LW, Saxon LA. Syncope in advanced heart failure: High risk of sudden death regardless of origin of syncope. J Am Coll Cardiol, 1993; 21: 110-116.
13. Middlekauff HR, Stevenson WG, Saxon LA. Prognosis after syncope: Impact of left ventricular function. Am Heart J, 1993; 125: 121-127.
14. Steinberg JS, Beckman K, Greene HL et al. Follow-up of patients with unexplained syncope and inducible ventricular tachyarrhythmias: Analysis of the AVID registry and an AVID substudy. antiarrhythmics versus implantable defibrillators. J Cardiovasc Electrophysiol, 2001; 12: 996-1001.
15. Andrews NP, Fogel RI, Pelargonio G, Evans JJ, Prystowsky EN. Implantable defibrillator event rates in patients with unexplained syncope and inducible sustained ventricular tachyarrhythmias: A comparison with patients known to have sustained ventricular tachycardia. J Am Coll Cardiol, 1999; 34: 2023-2030.
16. Link MS, Costeas XF, Griffith JL, Colburn CD, Estes NA 3rd, Wang PJ. High incidence of appropriate implantable cardiaverter - defibrillator therapy in patients with syncope of unknown etiology and inducible ventricular arrhythmias. J Am Coll Cardiol, 1997; 29: 370-375.
17. Knight BP, Goyal R, Pelosi F et al. Outcome of patients with nonischemic dilated cardiomyopathy and unexplained syncope treated with an implantable defibrillator. J Am Coll Cardiol, 1999; 33: 1964-1970.
18. Russo AM, Verdino R, Schorr C et al. Occurrence of implantable defibrillator events in patients with syncope and nonischemic dilated cardiomyopathy. Am J Cardiol, 2001; 88: 1444-1446.
19. Phang RS, Kang D, Tighiouart H, Estes NA 3rd, Link MS. High risk of ventricular arrhythmias in patients with nonischemic dilated cardiomyopathy presenting with syncope. Am J Cardiol, 2006; 97: 416-420.
20. Ellenbogen KA, Levine JH, Berger RD et al. Are implantable cardioverter defibrillator shocks a surrogate for sudden cardiac death in patients with nonischemic cardiomyopathy? Circulation, 2006; 113: 776-782.
21. Wathen MS, DeGroot PJ, Sweeney MO et al. Prospective randomized multicenter trial of empirical antitachycardia pacing versus shocks for spontaneous rapid ventricular tachycardia in patients with implantable cardioverter-defibrillators: Pacing fast ventricular tachycardia reduces shock therapies (PainFREE rx II) trial results. Circulation, 2004; 110: 2591-2596.
22. Olshansky B, Poole JE, Johnson G et al. Syncope predicts the outcome of cardiomyopathy patients: Analysis of the SCD-HeFT study. J Am Coll Cardiol, 2008; 51: 1277-1282.
23. Oh JH, Hanusa BH, Kapoor WN. Do symptoms predict cardiac arrhythmias and mortality in patients with syncope? Arch Intern Med, 1999; 159: 375-380.
24. Alboni P, Brignole M, Menozzi C et al. Diagnostic value of history in patients with syncope with or without heart disease. J Am Coll Cardiol, 2001; 37: 1921-1928.
25. Reiffel JA, Schwarzberg R, Murry M. Comparison of autotriggered memory loop recorders versus standard loop recorders versus 24-hour Holter monitors for arrhythmia detection. Am J Cardiol, 2005; 95: 1055-1059.
26. Rothman SA, Laughlin JC, Seltzer J et al. The diagnosis of cardiac arrhythmias: A prospective multi-center randomized study comparing mobile cardiac outpatient telemetry versus standard loop event monitoring. J Cardiovasc Electrophysiol, 2007; 18: 241-247.
27. Brignole M, Sutton R, Menozzi C et al. Early application of an implantable loop recorder allows effective specific therapy in patients with recurrent suspected neurally mediated syncope. Eur Heart J, 2006; 27: 1085-1092.
28. Krahn AD, Klein GJ, Yee R, Manda V. The high cost of syncope: Cost implications of a new insertable loop recorder in the investigation of recurrent syncope. Am Heart J, 1999; 137: 870-877.
29. Livanis EG, Kostopoulou A, Theodorakis GN et al. Neurocardiogenic mechanisms of unexplained syncope in idiopathic dilated cardiomyopathy. Am J Cardiol, 2007; 99: 558-562.
30. Brilakis ES, Shen WK, Hammill SC et al. Role of programmed ventricular stimulation and implantable cardioverter defibrillators in patients with idiopathic dilated cardiomyopathy and syncope. Pacing Clin Electrophysiol, 2001; 24: 1623-1630.
31. Fujimura O, Yee R, Klein GJ, Sharma AD, Boahene KA. The diagnostic sensitivity of electrophysiologic testing in patients with syncope caused by transient bradycardia. N Engl J Med, 1989; 321: 1703-1707.
32. Brugada P, Green M, Abdollah H, Wellens HJ. Significance of ventricular arrhythmias initiated by programmed ventricular stimulation: The importance of the type of ventricular arrhythmia induced and the number of premature stimuli required. Circulation, 1984; 69: 87-92.
33. Sanchez JM, Katsiyiannis WT, Gage BF et al. Implantable cardioverter-defibrillator therapy improves long-term survival in patients with unexplained syncope, cardiomyopathy, and a negative electrophysiologic study. Heart Rhythm, 2005; 2: 367-373.
34. Corrado D, Leoni L, Link MS et al. Implantable cardioverter-defibrillator therapy for prevention of sudden death in patients with arrhythmogenic right ventricular cordiomyopathy/dysplasia. Circulation, 2003; 108: 3084-3091.
35. Englund A, Bergfeldt L, Rosenqvist M. Pharmacologica] stress testing of the His-Purkinje system in patients with bifascicular block. Pacing Clin Electrophysiol, 1998; 21: 1979-1987.
36. Scheinman MM, Peters RW, Suave MJ et al. Value of the H-Q interval in patients with bundle branch block and the role of prophylactic permanent pacing. Am J Cardiol, 1982; 50: 1316-1322.
37. Brignole M, Menozzi C, Moya A et al. Mechanism of syncope in patients with bundle branch block and negative electrophysiological test. Circulation, 2001; 104: 2045-2050.
38. Menozzi C, Brignole M, Garcia-Civera R et al. Mechanism of syncope in patients with heart disease and negative electrophysiologic test. Circulation, 2002; 105: 2741-2745.
39. Link MS, Kim KM, Homoud MK, Estee NA 3rd, Wang PJ. Long - term outcome of patients with syncope associated with coronary artery disease and a nondiagnostic electrophysiologic evaluation. Am J Cardiol, 1999; 83: 1334-1337.
40. Fonarow GC, Feliciano Z, Boyle NG et al. Improved survival in patients with nonischemic advanced heart failure and syncope treated with an implantable cardioverter-defibrillator. Am J Cardiol, 2000; 85: 981-985.
41. Zipes DP, Camm AJ, Borggrefe M et al. European Heart Rhythm Association, Heart Rhythm Society, ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: A report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (writing committee to develop guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death). J Am Coll Cardiol, 2006; 48: e247-e346.
42. Gregoratos G, Abrams J, Epstein AE et al. ACC/AHA/NASPE 2002 guideline update for implantation of cardiac pacemakers and antiarrhythmia devices: Summary article: A report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines (ACC/AHA/ NASPE committee to update the 1998 pacemaker guidelines). Circulation, 2002; 106: 2145-2161.
43. Epstein AE, Baessler CA, Curtis AB et al. Addendum to "personal and public safety issues related to arrhythmias that may affect consciousness: Implications for regulation and physician recommendations. A medica/scientific statement from the American Heart Association and the North American Society of Pacing and Electrophysiology". Public safety issues in patients with implantable defibrillators. A scientific statement from the American Heart Association and the Heart Rhythm Society. Heart Rhythm, 2007; 4: 386-393.
44. Akiyama T, Powell JL, Mitchell LB, Ehlert FA, Baessler C. Antiarrhythmics versus implantable defibrillators investigators. Resumption of driving after life-threatening ventricular tachyarrhythmia. N Engl J Med, 2001; 345: 391-397.